期刊
JOURNAL OF ENDOCRINOLOGY AND METABOLISM
卷 9, 期 6, 页码 203-204出版社
ELMER PRESS INC
DOI: 10.14740/jem627
关键词
Mitochondrial diabetes; SGLT2 inhibitor; Empagliflozin
Recent animal studies have suggested that sodium-glucose co-transporter 2 (SGLT2) inhibitors have mitochondrial and cardiorenal protective effects. Herein we report the case of mitochondrial diabetes successfully treated with an SGLT2 inhibitor empagliflozin. Although the underlying mechanisms have still not been completely investigated, SGLT2 inhibitors may improve mitochondria' function, suppress oxidative stress and restore autophagy. SGLT2 inhibitors could be a treatment option for patients with mitochondrial diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据